Business Standard

BioNTech signs deal to co-develop OncoC4's cancer antibody drug

A late-stage trial for the drug has been planned for this year, the companies said

Biontech
Premium

Photo: Reuters

Reuters
Germany's BioNTech SE said on Monday that it signed a deal with privately held OncoC4 Inc to co-develop and commercialise its cancer antibody drug candidate.

OncoC4 will get a $200 million upfront payment and is eligible to receive development, regulatory and commercial milestone payments as well as double-digit tiered royalties.

The companies said they will co-develop the candidate, ONC-392, as a monotherapy or as a combination therapy in various cancer indications.

A late-stage trial for the drug has been planned for this year, the companies said.

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 20 2023 | 6:34 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com